Holen Sie sich die Stockscreener-App
44.67
1.99%
0.87
Handel nachbörslich:
44.67
Schlusskurs vom Vortag:
$43.80
Offen:
$42.75
24-Stunden-Volumen:
527.71K
Relative Volume:
1.03
Marktkapitalisierung:
$1.24B
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-7.347
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
-0.62%
1M Leistung:
+1.99%
6M Leistung:
+73.54%
1J Leistung:
+211.07%
1-Tages-Spanne:
$42.50
$46.27
1-Wochen-Bereich:
$42.00
$47.36
52-Wochen-Spanne:
$12.21
$52.47
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
44.67 | 1.21B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Anaptysbio CEO Faga sells $638k in shares - Investing.com
Anaptysbio CEO Faga sells $638k in shares By Investing.com - Investing.com India
Anaptysbio CLO Loumeau sells $98,809 in shares By Investing.com - Investing.com India
Anaptysbio CFO Mulroy sells $112k in shares By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 2,515 Shares - MarketBeat
Eric Loumeau Sells 2,210 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 14,281 Shares - MarketBeat
Anaptysbio CLO Loumeau sells $98,809 in shares - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Gap Down Following Insider Selling - MarketBeat
Is AnaptysBio Inc. stock positioned for digital transformationGrip and Outsole Review & HOKA model picks for your routine - ulpravda.ru
AnaptysBio (NASDAQ:ANAB) Upgraded at UBS Group - MarketBeat
AnaptysBio Moves to Toss GSK/Tesaro Repudiation Claim Over Jemperli Royalties - prismedia.ai
Anaptysbio CFO Mulroy sells $86k in shares By Investing.com - Investing.com Canada
What dividend safety score for AnaptysBio Inc. stockPortfolio Return Report & AI Optimized Trading Strategy Guides - ulpravda.ru
AnaptysBio CMO Lizzul sells $100k in stock By Investing.com - Investing.com UK
Anaptysbio chief legal officer Loumeau sells $439k in stock By Investing.com - Investing.com UK
Anaptysbio CFO Mulroy sells $86k in shares - Investing.com
Anaptysbio chief legal officer Loumeau sells $439k in stock - Investing.com
AnaptysBio CMO Lizzul sells $100k in stock - Investing.com
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - Reuters
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary - The Manila Times
AnaptysBio files motion to dismiss in Tesaro/GSK royalty dispute - Investing.com
AnaptysBio, Inc. Files Motion to Dismiss Breach of Contract Claim Amid Ongoing Dispute with Tesaro and GSK, Trial Set for July 2026 - Quiver Quantitative
Anaptys Files Motion to Dismiss Tesaro’s Claim of - GlobeNewswire
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 9,639 Shares - MarketBeat
Insider Selling: AnaptysBio (NASDAQ:ANAB) CEO Sells $415,102.22 in Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Sells $100,820.85 in Stock - MarketBeat
Why analysts upgrade AnaptysBio Inc. stockEarnings Growth Summary & Weekly High Conviction Trade Ideas - ulpravda.ru
Will AnaptysBio Inc. stock reach Wall Street targets2025 Market Sentiment & Accurate Intraday Trade Tips - ulpravda.ru
Can AnaptysBio Inc. stock sustain market leadershipRecession Risk & Daily Technical Forecast Reports - ulpravda.ru
Is AnaptysBio Inc. stock a buy in volatile marketsResistance Breakout Alerts & Build Balanced Portfolio - ulpravda.ru
UBS Raises AnaptysBio (ANAB) Price Target to $70, Upgrades to Buy | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's Why - MarketBeat
AnaptysBio stock rating initiated at Buy by UBS with $70 price target - Investing.com Canada
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
AnaptysBio (NASDAQ:ANAB) Insider Paul Lizzul Sells 4,219 Shares - MarketBeat
Anaptysbio CLO Eric Loumeau sells $129k in shares By Investing.com - Investing.com Canada
Anaptysbio CFO Mulroy sells $145k in shares By Investing.com - Investing.com Canada
Anaptysbio CEO Faga sells $662k in shares - Investing.com
Insider Selling: AnaptysBio (NASDAQ:ANAB) Insider Sells 2,983 Shares of Stock - MarketBeat
Anaptysbio CLO Eric Loumeau sells $129k in shares - Investing.com
AnaptysBio, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - Quiver Quantitative
AnaptysBio, Inc. $ANAB Shares Sold by Voya Investment Management LLC - MarketBeat
Is AnaptysBio Inc AN6 a good long term investmentTrading Volume Surges & High Profit Investment Ideas - earlytimes.in
New Highs: Is AnaptysBio Inc stock a safe haven assetEarnings Growth Report & AI Forecasted Stock Moves - moha.gov.vn
Anaptysbio CEO Faga sells $662k in shares By Investing.com - Investing.com Canada
This biotech stock has more than tripled in 2025, but red flags are waving - MSN
AnaptysBio (NASDAQ:ANAB) Stock Price Down 4%Should You Sell? - MarketBeat
Trade Alert: Independent Director Of AnaptysBio J. Ware Has Sold Stock - simplywall.st
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $51.58 - Investing.com
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):